- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Jon Hudson, MEDTHINK COMMUNICATIONS
Research shows that budget cuts on advertising and marketing during times of recession have a long term negative impact.
Jon Hudson
VICE PRESIDENT OF MEDIA AND DIGITAL SERVICES | MEDTHINK COMMUNICATIONS
Research shows that budget cuts on advertising and marketing during times of recession have a long term negative impact. There's an immediate short term savings, but the long term ROI suffers because the lack of visibility may further depress sales and reduce market share. Consistency of messaging is lost during times of relative silence, and companies must spend extra to regain their presence in the market once the economy brightens.
Jon Hudson
In fact, recessions are a time to find great deals. Publishers are more aggressive with rates and offer better positions and integrated campaigns for less dollars. Competitors are likely pulling back on their advertising. There is less clutter and noise in the marketplace and more opportunity for your company to stand out and carve a niche for itself.
If the decision makers can't be convinced that recessions present an opportunity, then it's time to integrate new technology that creates efficiencies, and saves time and money.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
